ISPC (iSpecimen) Moat Score: 2/10 (As of Jun. 29, 2026)


ISPC iSpecimen Inc ISPC
49 GF Score
Price $2.61
GF Value $6.72
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is iSpecimen Moat Score?

iSpecimen ISPC +5.53% 49 Moat Score is 2 as of Jun. 29, 2026. GuruFocus rates ISPC with a GF Score™ of 49/100 and a GF Value™ of $6.72 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, iSpecimen ranks better than 69.44% on this metric.

iSpecimen has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

iSpecimen has No Moat: iSpecimen Inc has minimal competitive advantages. The company lacks market leadership, significant customer switching costs, and durable cost advantages, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes iSpecimen might have No Moat - Very weak/transient advantages.

iSpecimen  (NAS:ISPC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

iSpecimen Moat Score Related Terms

ISPC vs BIAF, FUNI, IVRO: Moat Score Comparison

For the Diagnostics & Research subindustry, iSpecimen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iSpecimen Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Moat Score distribution charts can be found below:

* The bar in red indicates where iSpecimen's Moat Score falls into.


ISPC
49GF Score
iSpecimen Inc ISPC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
iSpecimen (ISPC) has a Moat Score of 2 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, iSpecimen ranks #66 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 30.6%.
Is iSpecimen's Moat Score too high?
iSpecimen's current Moat Score is 2. Based on the distribution chart, iSpecimen ranks #66 out of 216 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, iSpecimen has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does iSpecimen's Moat Score compare to BIAF and FUNI?
According to the Medical Diagnostics & Research industry distribution chart, iSpecimen ranks #66 out of 216 companies for Moat Score. This puts iSpecimen in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. iSpecimen's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iSpecimen stock overvalued right now?
Based on GuruFocus' analysis, iSpecimen (ISPC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.72, compared to a current price of $2.61 — trading 61.2% below its estimated fair value. The current Moat Score is 2. iSpecimen's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For iSpecimen (ISPC), the current Moat Score is 2 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iSpecimen (ISPC) Overvalued in 2026?

Based on GuruFocus' analysis, iSpecimen stock appears to be undervalued. The current stock price of $2.61 is trading 61.2% below its estimated GF Value™ of $6.72. GuruFocus considers iSpecimen to be Possible Value Trap.

Key valuation signals for ISPC:

  • Moat Score: 2
  • GF Value™: $6.72 vs. price of $2.61 (61.2% below fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ISPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iSpecimen Business Description

Address 8 Cabot Road, Suite 1800, Woburn, MA, USA, 01801
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
49GF Score

Get the complete analysis for ISPC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.61
Price
$6.72
GF Value